Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the company’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $476.34, for a total value of $3,953,622.00. Following the sale, the executive vice president owned 36,781 shares of the company’s stock, valued at approximately $17,520,261.54. This represents a 18.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Stock Up 0.9%

Shares of United Therapeutics stock traded up $4.47 on Thursday, reaching $480.52. The stock had a trading volume of 219,815 shares, compared to its average volume of 330,249. The stock has a market capitalization of $20.69 billion, a P/E ratio of 18.21, a P/E/G ratio of 2.57 and a beta of 0.85. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $519.99. The company has a 50 day moving average price of $485.84 and a 200 day moving average price of $437.55.

Analyst Ratings Changes

UTHR has been the topic of a number of recent analyst reports. Royal Bank Of Canada upped their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Wells Fargo & Company upped their target price on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. UBS Group reissued a “buy” rating on shares of United Therapeutics in a report on Tuesday. Finally, HC Wainwright lifted their target price on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $509.50.

Hedge Funds Weigh In On United Therapeutics

A number of large investors have recently bought and sold shares of UTHR. Avoro Capital Advisors LLC grew its stake in United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after acquiring an additional 383,838 shares during the period. Wellington Management Group LLP lifted its holdings in United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares in the last quarter. AQR Capital Management LLC grew its position in shares of United Therapeutics by 29.9% in the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after purchasing an additional 295,221 shares during the period. Invesco Ltd. increased its stake in shares of United Therapeutics by 90.2% during the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after purchasing an additional 419,588 shares in the last quarter. Finally, Janus Henderson Group PLC raised its position in shares of United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after purchasing an additional 341,383 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.